Related references
Note: Only part of the references are listed.A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions
Dean G. Brown et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.
Mark Lythgoe et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval
Kerrington Powell et al.
JAMA ONCOLOGY (2021)
Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019
Mark P. Lythgoe et al.
DRUG DISCOVERY TODAY (2021)
Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.
Ali Raza Khaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Medical Care Costs Associated with Cancer Survivorship in the United States
Angela B. Mariotto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Project Orbis: Global Collaborative Review Program
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2020)
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
Thomas J. Hwang et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
Bishal Gyawali et al.
JAMA INTERNAL MEDICINE (2019)
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review
Julia A. Beaver et al.
JAMA ONCOLOGY (2018)
Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
Huseyin Naci et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015
Nicholas S. Downing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
Austin Lammers et al.
BLOOD CANCER JOURNAL (2017)
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
Aaron S. Kesselheim et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
Aaron S. Kesselheim et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Sham Mailankody et al.
JAMA ONCOLOGY (2015)
How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views
G. Tafuri et al.
ANNALS OF ONCOLOGY (2014)
Era Of Faster FDA Drug Approval Has Also Seen Increased Black-Box Warnings And Market Withdrawals
Cassie Frank et al.
HEALTH AFFAIRS (2014)
Regulatory Review of Novel Therapeutics - Comparison of Three Regulatory Agencies
Nicholas S. Downing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
How Does Medical Device Regulation Perform in the United States and the European Union? A Systematic Review
Daniel B. Kramer et al.
PLOS MEDICINE (2012)
Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe
Samantha A. Roberts et al.
HEALTH AFFAIRS (2011)
Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?
Elizabeth A. Richey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
